Sampling Variability on Percutaneous Liver Biopsy in Patients with Chronic Hepatitis C Virus Infection

References

• Fanning L, Loane J, Kenny-Walsh E, Sheehan M, Whelton M, Kirwan W, et al. Tissue viral load variability in chronic hepatitis C. Am J Gastroenterol 2001; 96: 3384–9.
   PubMed Web of Science ®Google Scholar
• Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1979; 139: 667–9.
   PubMedGoogle Scholar
• Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523–5.
   PubMed Web of Science ®Google Scholar
• Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996; 49: 556–9.
   PubMed Web of Science ®Google Scholar
• Olsson R, Hagerstrand I, Broome U, Danielsson A, Jarnerot G, Loof L, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995; 48: 933–5.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S–10S.
   Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–62.
   PubMed Web of Science ®Google Scholar
• Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S–61S.
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131–7.
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, META VIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–32.
   PubMed Web of Science ®Google Scholar
• Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477–81.
   Google Scholar
• Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci 1989; 34: 322–3.
   PubMed Web of Science ®Google Scholar
• Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978; 74: 103–6.
   PubMed Web of Science ®Google Scholar
• Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–17.
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–5.
   PubMed Web of Science ®Google Scholar
• Regev A, Bertio M, Jeffers LJ, Clara M, Neff GW, Civantos F, et al. Sampling error associated with a needle liver biopsy in patients with chronic hepatitis C virus infection [abstract]. Hepatology 1999; 30 Suppl: 270A.
   Google Scholar
• Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241–6.
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513–20.
   PubMed Web of Science ®Google Scholar
• Idrovo V, Dailey PJ, Jeffers LJ, Coelho-Little E, Beinstein D, Bartholomew M, et al. Hepatitis C virus RNA quantification in right and left lobes of the liver in patients with chronic hepatitis C. J Viral Hepatol 1996; 3: 239–46.
   PubMed Web of Science ®Google Scholar
• Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997; 78 Pt 6: 1341–7.
   PubMed Web of Science ®Google Scholar
• Hasan F, Askar H, Al Khalidi J, Al Shamali M, Al Kalaòui M, Al Nakib B. Lack of transmission of hepatitis C virus following needlestick accidents. Hepatogastroenterology 1999; 46: 1678–81.
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an ‘a la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211–8.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12–7.
   PubMed Web of Science ®Google Scholar
• Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088–94.
   PubMed Web of Science ®Google Scholar
• Bonis PA, Ioannidis JP, Cappelleri JC, Kaplan MM, Lau J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997; 26: 1035–44.
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780–5.
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164–72.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–81.
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332: 1457–62.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Shiffman M, et al. Baseline alanine aminotransferase level predicts histologic and serologic response in patients with HBeAg- Positive chronic hepatitis B treated with adefovir dipivoxil [abstract]. J Hepatol 2002; 36 Suppl 1: 122–3.
   Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–13.
   PubMed Web of Science ®Google Scholar
• Siddique I, El-Naga H, Madda JP, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection [abstract]. Gastroenterology 2002; 122 Supp 1: A-630.
   Google Scholar